CLS awarded as Industry Partner in NIH-Funded Five-Year Research Program in U.S to Advance MR-Guided Laser Therapy for Spinal Metastases
Clinical Laserthermia Systems AB (publ) (“CLS”), together with ClearPoint Neuro Inc., is participating as an industry partner in a five-year research collaboration led by Dartmouth Health and supported by the U.S. National Cancer Institute (NCI). The collaboration aims to advance MR-guided laser interstitial thermal therapy (LITT) for patients with spinal metastases.
The five-year $2.98 million competitively awarded NCI R01 program led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases¹, in which CLS is an industry partner, progresses from laboratory and pre-